scholarly journals The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
K. C. M. Perera ◽  
N. Mapitigama ◽  
HTCS Abeysena
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Test ◽  
Screening Method ◽  
Married Women ◽  
Cross Sectional ◽  
Dna Test ◽  
Hpv Dna ◽  
Hpv Dna Test

Abstract Background Cervical cancer is the second commonest female cancer in Sri Lanka. Two major drawbacks of the present cervical cancer screening programme are the suboptimal sensitivity of the pap smear and the low coverage. The objective of the study is to determine the feasibility of a new HPV/DNA test among 35 -years -old ever-married women in a district of Sri Lanka. Method A community based descriptive cross-sectional study was conducted from 1stof July 2018 to 30th November 2018 in the public health divisions called Medical Officer of Health (MOH) areas of Kalutara district. The study population is comprised of ever-married women 35 years of age. Three women from each cluster (n = 413) were selected by consecutive sampling. A total of 918 women were recruited. HPV/DNA cervical specimen collection (n = 822) was carried out. Cervical specimens were tested by two cytoscreeners with the cobas 4800 PCR based screening machine. Clients’ perceptions and prevalence were assessed. The follow-up of women with positive HPV/DNA screening results was carried out. The operational and technical feasibility of the screening test were assessed. Data entry was done by using the statistical package IBM SPSS version 20. Results Overall response rate was 91.1% (n = 836). Clients’ perception was highly positive for HPV/DNA screening test procedure (99.9%, n = 821) and 99.6% (n = 819) of clients had mentioned that the HPV/DNA screening test is worthwhile to be incorporated into the National Cervical Cancer Screening program. The prevalence of HPV was 6.2% (95%CI: 6.18–6.22%). The coverage of the HPV/DNA screening was 89.5%(n = 822). Invalid results reported were 0.12% (n = 1). The percentage of HPV/DNA test positive women who underwent pap test within 3 months of the initial screening was 100% (n = 51), while the percentage of women who attempted to get a colposcopy within the 1 month of referral was 86.7% (n = 13). Conclusions HPV/DNA test implementation as a primary cervical cancer screening method is feasible among the 35- year age cohort of ever- married women in Kalutara district. It is necessary to further attempt alternative methods of cobas 4800 HPV/DNA test, which would be much suitable for resource-limited settings.

Population-based cervical cancer screening using high-risk HPV DNA test and liquid-based cytology in Northern Thailand

Pathology ◽  
2014 ◽  
Vol 46 ◽  
pp. S68
Author(s):  
Sumalee Siriaunkgul ◽  
Jongkolnee Settakorn ◽  
Kornkanok Sukpun ◽  
Jatupol Srisomboon ◽  
Prapaporn Suprasert ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Population Based ◽  
Dna Test ◽  
Hpv Dna ◽  
Liquid Based Cytology ◽  
High Risk Hpv ◽  
Hpv Dna Test

scholarly journals Evaluation of a new p16INK4A ELISA test and a high-risk HPV DNA test for cervical cancer screening: Results from proof-of-concept study

2007 ◽  
Vol 120 (11) ◽  
pp. 2435-2438 ◽  
Author(s):  
Constance Mao ◽  
Akhila Balasubramanian ◽  
Mujun Yu ◽  
Nancy Kiviat ◽  
Ruediger Ridder ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Elisa Test ◽  
Proof Of Concept ◽  
Dna Test ◽  
Hpv Dna ◽  
High Risk Hpv ◽  
Hpv Dna Test

scholarly journals Efficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening

2003 ◽  
Vol 120 (4) ◽  
pp. 492-499 ◽  
Author(s):  
Patricia de Cremoux ◽  
Joël Coste ◽  
Xavier Sastre-Garau ◽  
Martine Thioux ◽  
Christelle Bouillac ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Hybrid Capture ◽  
Dna Test ◽  
Hpv Dna ◽  
Hybrid Capture 2 ◽  
Hpv Dna Test

scholarly journals Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand

2014 ◽  
Vol 15 (16) ◽  
pp. 6837-6842 ◽  
Author(s):  
Sumalee Siriaunkgul ◽  
Jongkolnee Settakorn ◽  
Kornkanok Sukpan ◽  
Jatupol Srisomboon ◽  
Prapaporn Suprasert ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Population Based ◽  
Dna Test ◽  
Hpv Dna ◽  
Liquid Based Cytology ◽  
High Risk Hpv ◽  
Hpv Dna Test

scholarly journals The prevalence of hrHPV among the isolated community in the Highland of Bario, Sarawak, East Malaysia

2020 ◽  
Author(s):  
Abigail Rembui Jerip ◽  
Mardiana Kipli ◽  
Nadia Diyana Hamzah New ◽  
Cheng-Siang Tan
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Low Resource Settings ◽  
Dna Test ◽  
Hpv Dna ◽  
Low Resource ◽  
East Malaysia ◽  
Hpv Dna Test

Abstract Background Malaysia has introduced the free Pap smear as the primary cervical cancer screening program since the 1960s but has only achieved the national coverage of 22%. The coverage would be much lower in the rural communities especially in Sarawak where many villages and communities are still living in low resource settings and inaccessible by road. In this study, we have evaluated Qiagen’s careHPV system as a point-of-careHPV diagnostic test together with the visualization using acetic acid (VIA) in the isolated communities in the Highland of Bario, Sarawak, East Malaysia. Methods Women attending the cervical cancer outreach program were recruited. Consent was obtained and a cervical swab was clinician-collected and screened for High-risk HPV DNA using the careHPV system. Cervical examination using VIA was offered to all women age <50-year. hrHPV positive women were recruited during their follow-up session and the second cervical swab was collected for HPV genotyping using consensus primer-nested PCR to elucidate the infecting HPV genotypes. Results Seventy-five women aged 27-83 (mean age 55) attended the cervical cancer screening clinic and 8% (n=6/75) of them were positive for hrHPV. Only 33 women were screened using VIA and 21.2% (n=7/33) were found to be positive. A majority of the women (58.6%) were above the age of 50-year and not recommended for VIA to be performed. Thus, it was not feasible to correlate the results obtained from the HPV DNA test and VIA. Only four hrHPV positive women returned for follow-up and genotyping revealed HPV52 in 2 of four women tested suggesting that HPV52 may be the predominant genotype in Bario. Conclusions The careHPV system is portable and can be used in low resource settings as long as reliable electricity is available. We found that careHPV HPV DNA test is more objective compared to VIA and can be used to screen women outside the recommended eligible age. This is especially true for older women in the rural who have never had any form of cervical cancer screening before.

scholarly journals The prevalence of hrHPV among the isolated community in the Highland of Bario, Sarawak, East Malaysia

2019 ◽  
Author(s):  
Abigail Rembui Jerip ◽  
Mardiana Kipli ◽  
Cheng-Siang Tan
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Outreach Program ◽  
Low Resource Settings ◽  
Dna Test ◽  
Hpv Dna ◽  
Low Resource ◽  
Cervical Swab

Abstract Background Malaysia has introduced the free Pap smear as the primary cervical cancer screening program since the 1960s but has only achieved the national coverage of 22%. The coverage would be much lower in the rural communities especially in Sarawak where many villages are still inaccessible by road, and communities are living in low resource settings. In this study, we have evaluated Qiagen’s careHPV system as a point-of-care HPV diagnostic test together with the visualization using acetic acid (VIA) in the isolated community in the Highland of Bario which are predominantly from the Kelabit ethnicity. Methods Women attending the cervical cancer outreach program were recruited. Consent was obtained and a cervical swab was clinician-collected and screened for High-risk HPV DNA using the careHPV system. Cervical examination using VIA was offered to all women age <50-year. hrHPV positive women were recruited during their follow-up session and the second cervical swab was collected for HPV genotyping using consensus primer-nested PCR to elucidate the infecting HPV genotypes. Results Seventy-five women from the age of 27-83 (mean age 55) attended the cervical cancer screening clinic and 8% (n=6/75) of them were positive for hrHPV. Only 33 women were screened using VIA and 21.2% (n=7/33) were found to be positive. A majority of the women (58.6%) were above the age of 50-year and not recommended for VIA to be performed. Thus, it was not feasible to correlate the results obtained from the HPV DNA test and VIA. Only four hrHPV positive women returned for follow-up and genotyping revealed HPV52 in 2 of four women tested suggesting that HPV52 may be the predominant genotype in Bario. Conclusions The careHPV system is portable and can be used in low resource settings as long as reliable electricity is available. We found that careHPV DNA test is more objective compared to VIA and can be used to screen women outside the recommended eligible age. This is especially true for older women in the rural who have never had any form of cervical cancer screening before.

Sign in / Sign up

Export Citation Format

Share Document